Skip to main content
Erschienen in:

20.12.2021 | short review

BTKi, venetoclax, obinutuzumab: what is the ideal combination?

verfasst von: Daniel Heintel, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Summary

Chronic lymphocytic leukemia (CLL) treatment strategies have improved and changed dramatically in the last few years. Currently, patients are mostly treated with so-called novel agents, including Bruton tyrosin kinase (BTK) inhibitors and BCL‑2 inhibitors. CLL is a chronic disease; therefore, a proportion of patients will require multiple lines of therapy. In this review, we present the current treatment options for patients with CLL and discuss potential optimal treatment combinations.
Literatur
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Metadaten
Titel
BTKi, venetoclax, obinutuzumab: what is the ideal combination?
verfasst von
Daniel Heintel, MD
Publikationsdatum
20.12.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00776-4